aspirin has been researched along with Preterm Birth in 111 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas trial was a landmark study that demonstrated a reduction in preterm birth and hypertensive disorders of pregnancy in nulliparous women who received low-dose aspirin." | 9.69 | The impact of risk factors on aspirin's efficacy for the prevention of preterm birth. ( Achieng, E; Bauserman, M; Bucher, S; Carlo, WA; Chomba, E; Das, P; Derman, RJ; Esamai, F; Figueroa, L; Goco, N; Goldenberg, RL; Goudar, SS; Hemingway-Foday, J; Hibberd, PL; Hoffman, MK; Jessani, S; Kavi, A; Krebs, NF; Kurhe, K; Liechty, EA; Lokangaka, A; McClure, EM; Metgud, M; Moore, J; Nuss, EE; Nyongesa, P; Okitawutshu, J; Saleem, S; Silver, RM; Somannavar, M; Tembo, AM; Tshefu, A, 2023) |
| "Low dose aspirin (LDA) is an effective strategy to reduce preterm birth." | 9.51 | The efficacy of low-dose aspirin in pregnancy among women in malaria-endemic countries. ( Bauserman, M; Bose, CL; Carlo, WA; Chomba, E; Derman, RJ; Esamai, F; Goldenberg, RL; Hemingway-Foday, J; Hoffman, M; Jessani, S; Koso-Thomas, M; Leuba, SI; Liechty, EA; Lokangaka, A; McClure, EM; Meshnick, SR; Moore, J; Nolen, TL; Patterson, J; Saleem, S; Tsehfu, A, 2022) |
| "This systematic review and meta-analysis investigated whether the use of low-dose aspirin during pregnancy by women with chronic hypertension reduces the odds of superimposed preeclampsia and poor perinatal outcomes." | 9.41 | Low-dose aspirin for the prevention of superimposed preeclampsia in women with chronic hypertension: a systematic review and meta-analysis. ( Giorgione, V; Richards, EMF; Stevens, O; Thilaganathan, B, 2023) |
| " The secondary outcomes included gestational hypertension; fetal growth restriction; preterm birth, either spontaneous or iatrogenic, before 34 weeks of gestation; gestational age at birth; neonatal birthweight; and adverse events secondary to the administration of aspirin, including antepartum and postpartum hemorrhage." | 9.41 | Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis. ( Acuti Martellucci, C; Buca, D; Cerra, C; D'Antonio, F; Fichera, A; Flacco, ME; Herrera, M; Khalil, A; Morelli, R; Orabona, R; Prefumo, F; Rizzo, G, 2023) |
| "Compared with aspirin alone, low-dose aspirin combined with calcium supplementation was more effective in preventing preeclampsia, reduced the risk of preterm birth and postpartum hemorrhage, and promoted fetal growth." | 9.41 | Clinical efficacy of low-dose aspirin combined with calcium in preventing preeclampsia: A systematic review and meta-analysis. ( Chen, WY; Sun, SF, 2023) |
| "To examine the possible risk factors amongst maternal characteristics, medical and obstetric history, pre-eclampsia (PE)-specific biomarkers and estimated-risk group, according to The Fetal Medicine Foundation (FMF) algorithm, that are associated with the development of preterm PE with delivery at < 37 weeks' gestation despite aspirin prophylaxis." | 9.41 | ASPRE trial: risk factors for development of preterm pre-eclampsia despite aspirin prophylaxis. ( Martinez-Portilla, RJ; Poon, LC; Rolnik, DL; Shen, L, 2021) |
| " Meta-analyses of low-dose aspirin to prevent pre-eclampsia suggest that the incidence of preterm birth might also be decreased, particularly if initiated before 16 weeks of gestation." | 9.34 | Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. ( Achieng, E; Bose, CL; Carlo, WA; Chicuy, J; Chomba, E; Das, P; Derman, RJ; Esamai, F; Figueroa, L; Garces, A; Goco, N; Goldenberg, RL; Goudar, SS; Hemingway-Foday, J; Hibberd, PL; Hoffman, MK; Jessani, S; Kodkany, BS; Koso-Thomas, M; Krebs, NF; Kurhe, K; Liechty, EA; Lokangaka, A; McClure, EM; Metgud, M; Miodovnik, M; Moore, J; Mwapule, A; Mwenechanya, M; Nolen, TL; Nyongesa, P; Okitawutshu, J; Patel, A; Saleem, S; Silver, R; Somannavar, M; Tshefu, A; Zehra, F, 2020) |
| " The subjects of the study were randomly assigned into two groups of intervention and control to receive either 80 mg of aspirin or placebo daily during the pregnancy." | 9.34 | The effect of aspirin on preeclampsia, intrauterine growth restriction and preterm delivery among healthy pregnancies with a history of preeclampsia. ( Abdi, N; Alavi, A; Asadi, N; Hessami, K; Kasraeian, M; Rozrokh, A; Vafaei, H; Zare, S, 2020) |
| "Our objective was to determine whether low-dose aspirin reduces the rate of spontaneous preterm birth in nulliparous women without medical comorbidities." | 9.27 | Low-dose aspirin is associated with reduced spontaneous preterm birth in nulliparous women. ( Andrikopoulou, M; Gyamfi-Bannerman, C; Handal-Orefice, R; Purisch, SE, 2018) |
| " Trial will be individually randomized with one-to-one ratio (intervention/control) Population: Nulliparous women between the ages of 14 and 40, with a singleton pregnancy between 6 0/7 weeks and 13 6/7 weeks gestational age (GA) confirmed by ultrasound prior to enrollment, no more than two previous first trimester pregnancy losses, and no contraindications to aspirin." | 9.24 | A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study. ( Bose, CL; Carlo, WA; Chomba, E; Derman, RJ; Esamai, F; Garces, A; Goco, N; Goldenberg, RL; Goudar, SS; Hambidge, KM; Hemingway-Foday, JJ; Hibberd, PL; Hoffman, MK; Kodkany, BS; Koso-Thomas, M; Krebs, NF; Liechty, EA; Lokangaka, A; McClure, EM; Miodovnik, M; Mwenechanya, M; Patel, A; Saleem, S; Silver, R; Tshefu, A; Wallace, DD, 2017) |
| "To examine whether combined treatment with low-molecular-weight heparin (LMWH) and aspirin reduces recurrent hypertensive disorders of pregnancy (HD: pre-eclampsia, eclampsia or HELLP syndrome) in women with antiphospholipid antibodies (aPLA) and a previous delivery for HD and/or small-for-gestational-age (SGA) birthweight before 34 weeks gestation." | 9.22 | Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. ( Bezemer, D; de Vries, JI; Hague, WM; van Hoorn, ME; van Pampus, MG, 2016) |
| "The objective of this study is to determine whether low-dose aspirin (LDA) reduced the rate of preterm birth (PTB) in a cohort of women at high risk for preeclampsia." | 9.22 | The impact of low-dose aspirin on preterm birth: secondary analysis of a randomized controlled trial. ( Allshouse, AA; Heyborne, KD; Jessel, RH, 2016) |
| "Aspirin supplementation was associated with worse outcomes related to preterm birth in smokers in a high-risk but not low-risk cohort." | 9.20 | Low-dose aspirin, smoking status, and the risk of spontaneous preterm birth. ( Abramovici, A; Biggio, J; Cantu, J; Edwards, R; Jauk, V; Tita, A; Wetta, L, 2015) |
| "To evaluate the association between low-dose aspirin initiated before conception and the risk of preterm birth." | 9.20 | Low-dose aspirin and preterm birth: a randomized controlled trial. ( Ahrens, K; Faraggi, D; Galai, N; Lesher, LL; Lynch, AM; Mumford, SL; Perkins, NJ; Schisterman, EF; Silver, RM; Sjaarda, L; Townsend, JM; Wactawski-Wende, J; Wong, LF, 2015) |
| "To estimate the effect of early administration of aspirin on the prevention of pre-eclampsia in high-risk women." | 9.20 | Early prediction and aspirin for prevention of pre-eclampsia (EPAPP) study: a randomized controlled trial. ( Goetzinger, KR; Odibo, AO; Odibo, L; Tuuli, MG, 2015) |
| "To evaluate the effect of low-dose aspirin in prevention of adverse pregnancy outcomes (APO) in women with second trimester alpha-fetoprotein (AFP) >2." | 9.19 | Effect of aspirin in prevention of adverse pregnancy outcome in women with elevated alpha-fetoprotein. ( Alavi, A; Borna, S; Hantoushzadeh, S; Khazardoost, S; Khezerlou, N; Mousavi, S, 2014) |
| "Diagnosis of preeclampsia; adverse pregnancy health outcomes and complications including eclampsia, perinatal mortality, preterm birth, small for gestational age, and potential bleeding harms or infant/child harms from aspirin exposure." | 9.12 | Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. ( Henderson, JT; Redmond, N; Senger, CA; Thomas, RG; Vesco, KK, 2021) |
| " Aspirin prophylaxis substantially lowered the risk of pre-eclampsia, preterm birth, perinatal mortality, and intrauterine growth retardation without elevated bleeding risks." | 9.12 | Aspirin Prophylaxis During Pregnancy: A Systematic Review and Meta-Analysis. ( Choi, YJ; Shin, S, 2021) |
| "In high-risk pregnancies, early aspirin intervention starting before 16 weeks of gestation can prevent PIH, preeclampsia, IUGR, and preterm birth and help to increase the birth weight." | 8.91 | [Early intervention with aspirin for preventing preeclampsia in high-risk women: a meta-analysis]. ( Wu, H; Yao, S; Yu, Y, 2015) |
| "To estimate the effect of low-dose aspirin started in early pregnancy on the incidence of preeclampsia and intrauterine growth restriction (IUGR)." | 8.86 | Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. ( Audibert, F; Bujold, E; Bureau, M; Forest, JC; Giguère, Y; Lacasse, Y; Marcoux, S; Roberge, S, 2010) |
| "This study aimed to investigate the association between low-dose aspirin use and preterm birth among women with a previous preterm birth." | 8.31 | Low-dose aspirin use in pregnancy and the risk of preterm birth: a Swedish register-based cohort study. ( Bergman, L; Hastie, R; Hesselman, S; Kupka, E; Lomartire, R; Wikström, AK, 2023) |
| "This study aimed to evaluate whether there is an association between the US Preventive Services Taskforce aspirin guideline hypertensive disorders of pregnancy and the rates of hypertensive disorders of pregnancy and preterm birth in individuals with pregestational diabetes mellitus." | 8.31 | Hypertensive disorders of pregnancy pre- and postaspirin guideline publication in individuals with pregestational diabetes mellitus. ( Allshouse, AA; Bruno, AM; Metz, TD; Theilen, LH, 2023) |
| "Prophylactic low-dose aspirin reduces the rates of preeclampsia, preterm birth, fetal growth restriction, and perinatal death in patients with risk factors for preeclampsia." | 8.31 | Society for Maternal-Fetal Medicine Special Statement: Prophylactic low-dose aspirin for preeclampsia prevention-quality metric and opportunities for quality improvement. ( Combs, CA; Kumar, NR; Morgan, JL, 2023) |
| "The USPSTF concludes with moderate certainty that there is a substantial net benefit of daily low-dose aspirin use to reduce the risk for preeclampsia, preterm birth, small for gestational age/intrauterine growth restriction, and perinatal mortality in pregnant persons at high risk for preeclampsia." | 8.02 | Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement. ( Barry, MJ; Cabana, M; Caughey, AB; Davidson, KW; Davis, EM; Donahue, KE; Doubeni, CA; Kubik, M; Li, L; Mangione, CM; Ogedegbe, G; Pbert, L; Silverstein, M; Simon, MA; Stevermer, J; Tseng, CW; Wong, JB, 2021) |
| " Among 932 women, 277 in the First Affiliated Hospital of Chongqing Medical University were routinely treated with aspirin (100 mg daily) from 12 to 16 weeks to 35 weeks of gestational age, while 655 in Chongqing Health Center for Women and Children were not taking aspirin during pregnancy." | 8.02 | Low-dose aspirin for primary prevention of adverse pregnancy outcomes in twin pregnancies: an observational cohort study based on propensity score matching. ( Baker, P; Kilby, MD; Liu, X; Liu, Y; Qi, H; Saffery, R; Tong, C; Wang, L; Wen, L; Ye, Y, 2021) |
| "Women with lupus have an increased risk of preeclampsia and preterm birth, and aspirin 81 mg/day is recommended as a preventative measure for preeclampsia." | 7.91 | Effect of aspirin response signature gene expression on preterm birth and preeclampsia among women with lupus: a pilot study. ( Clowse, MEB; Eudy, AM; Myers, RA; Voora, D, 2019) |
| "The beneficial effect of aspirin in the prevention of preterm preeclampsia may not apply in pregnancies with chronic hypertension." | 7.85 | Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. ( Akolekar, R; De Stefani, L; Delgado, JL; Evangelinakis, N; Gonzalez-Vanegas, O; Jani, JC; Leipold, G; Nicolaides, KH; Persico, N; Plasencia, W; Poon, LC; Rolnik, DL; Shearing, S; Syngelaki, A; Tsokaki, T; Wright, D, 2017) |
| "The incidence of preterm preeclampsia was 1." | 7.30 | Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial. ( Alsius, M; Bonacina, E; Caamiña, S; Carreras, E; de Mingo, L; Diaz, S; Ferrer-Costa, R; Garcia, E; Garcia-Manau, P; López, M; Lopez-Quesada, E; Maiz, N; Maroto, A; Martin, L; Mendoza, M; Millán, P; Ocaña, V; Orizales-Lago, C; Pallarols, M; Pérez-Gomez, A; Pintado, E; Puerto, L; Ricart, M; Rodríguez-Zurita, A; Suy, A; Teixidor, M; Vidal-Sagnier, L; Vives, À, 2023) |
| "The risk of preeclampsia was not different when comparing the aspirin and placebo groups among the Hispanic, non-Hispanic black, or other ethnicity and race groups." | 6.94 | Low-dose aspirin for preeclampsia prevention: efficacy by ethnicity and race. ( Aagaard, KM; Mendez-Figueroa, H; Sangi-Haghpeykar, H; Tolcher, MC, 2020) |
| "The Aspirin for Evidence-Based Preeclampsia Prevention trial data are consistent with the hypothesis that aspirin delays the gestational age at delivery with preeclampsia." | 6.90 | Aspirin delays the development of preeclampsia. ( Nicolaides, KH; Wright, D, 2019) |
| "When aspirin was initiated at > 16 weeks, with a dosage of < 100 mg/day aspirin, there was a lesser preventive effect (RR = 0." | 6.82 | The role of aspirin dose and initiation time in the prevention of preeclampsia and corresponding complications: a meta-analysis of RCTs. ( Dai, C; He, Q; Huang, X; Lee, W; Li, L; Li, R; Luo, Z; Mok, TN; Yip, KC; Zeng, W, 2022) |
| "Placental insufficiency affects about 10% of pregnancies and can lead to pre-eclampsia, fetal growth restriction, and preterm birth." | 6.82 | The role of melatonin in pregnancies complicated by placental insufficiency: A systematic review. ( Bussolaro, S; Fantasia, I; Rolnik, DL; Stampalija, T, 2022) |
| "Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality." | 6.50 | Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. ( Henderson, JT; O'Connor, E; Rowland, MG; Senger, CA; Thompson, JH; Whitlock, EP, 2014) |
| "Premature birth is associated with an increased risk of mortality and morbidity, and strategies to prevent preterm birth are few in number and resource intensive." | 5.91 | Cost-effectiveness of low-dose aspirin for the prevention of preterm birth: a prospective study of the Global Network for Women's and Children's Health Research. ( Achieng, E; Bose, CL; Bresnahan, BW; Bucher, S; Carlo, WA; Chicuy, J; Chomba, E; Das, P; Derman, RJ; Esamai, F; Figueroa, L; Goco, N; Goldenberg, RL; Goudar, SS; Hibberd, PL; Hoffman, M; Jessani, S; Kavi, A; Koso-Thomas, M; Krebs, NF; Kurhe, K; Liechty, EA; Lokangaka, A; McClure, EM; Metgud, M; Moore, J; Mwapule, A; Mwenechanya, M; Neuwahl, S; Nyongesa, P; Okitawutshu, J; Patel, A; Patterson, JK; Saleem, S; Somannavar, M; Tshefu, A, 2023) |
| "The Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas trial was a landmark study that demonstrated a reduction in preterm birth and hypertensive disorders of pregnancy in nulliparous women who received low-dose aspirin." | 5.69 | The impact of risk factors on aspirin's efficacy for the prevention of preterm birth. ( Achieng, E; Bauserman, M; Bucher, S; Carlo, WA; Chomba, E; Das, P; Derman, RJ; Esamai, F; Figueroa, L; Goco, N; Goldenberg, RL; Goudar, SS; Hemingway-Foday, J; Hibberd, PL; Hoffman, MK; Jessani, S; Kavi, A; Krebs, NF; Kurhe, K; Liechty, EA; Lokangaka, A; McClure, EM; Metgud, M; Moore, J; Nuss, EE; Nyongesa, P; Okitawutshu, J; Saleem, S; Silver, RM; Somannavar, M; Tembo, AM; Tshefu, A, 2023) |
| " Low-dose aspirin is used to prevent pre-eclampsia, which has a similar mechanism; hence, the present study aimed to investigate the effect of low-dose aspirin on the prevention of PTD in women with a history of spontaneous PTD." | 5.69 | Evaluation of the Effect of Low-dose Aspirin on the Prevention of Preterm Delivery in Women with a History of Spontaneous Preterm Delivery. ( Azadi, P; Bakhtiyari, M; Dehghani, Z; Khavandegar, A; Mirzamoradi, M; Mohammadi, M, 2023) |
| "· High-risk patients who lack a history preeclampsia were less likely to be advised of aspirin use." | 5.62 | Improving Utilization of Aspirin for Prevention of Preeclampsia in a High-Risk Urban Cohort: A Prospective Cohort Study. ( Berghella, V; Boelig, RC; Roman, A; Wanees, M; Zhan, T, 2021) |
| "In this study, we observed that low-dose aspirin did not significantly reduce the preterm birth rate in women with a previous spontaneous preterm birth." | 5.51 | Evaluation of low-dose aspirin in the prevention of recurrent spontaneous preterm labour (the APRIL study): A multicentre, randomised, double-blinded, placebo-controlled trial. ( Bekker, MN; Boon, J; de Boer, MA; de Groot, CJM; Franssen, MTM; Hemels, MAC; Hermes, W; Huisjes, AJM; Kleiverda, G; Landman, AJEMC; Mol, BW; Naaktgeboren, CN; Nijman, TAJ; Oudijk, MA; Papatsonis, DNM; Sikkema, JM; Sueters, M; van der Ham, DP; van der Weide, MC; van Drongelen, J; van Huizen, ME; van Laar, JOEH; van Pampus, MG; Visser, H; Visser, L; Zwart, JJ, 2022) |
| "Low dose aspirin (LDA) is an effective strategy to reduce preterm birth." | 5.51 | The efficacy of low-dose aspirin in pregnancy among women in malaria-endemic countries. ( Bauserman, M; Bose, CL; Carlo, WA; Chomba, E; Derman, RJ; Esamai, F; Goldenberg, RL; Hemingway-Foday, J; Hoffman, M; Jessani, S; Koso-Thomas, M; Leuba, SI; Liechty, EA; Lokangaka, A; McClure, EM; Meshnick, SR; Moore, J; Nolen, TL; Patterson, J; Saleem, S; Tsehfu, A, 2022) |
| "This is a follow-up study of the Dutch double-blind randomised controlled APRIL trial which assessed the effectiveness of treatment with aspirin (80 mg daily) compared with placebo for the prevention of preterm birth in women with a previous spontaneous preterm birth." | 5.51 | Long-term outcomes following antenatal exposure to low-dose aspirin: study protocol for the 4-year follow-up of the APRIL randomised controlled trial. ( de Boer, MA; Finken, MJJ; Landman, AJEMC; Leemhuis, AG; Oosterlaan, J; Oudijk, MA; Painter, RC; Pajkrt, E; Ravelli, ACJ; Roseboom, TJ; van 't Hooft, J; van Baar, AL; van Limburg Stirum, EVJ; van Wely, M, 2022) |
| "The Aspirin for Evidence-Based Preeclampsia Prevention trial was a multicenter study in women with singleton pregnancies." | 5.46 | Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. ( Carbone, IF; de Alvarado, M; Delgado, JL; Dutemeyer, V; Kapeti, E; Nicolaides, KH; Papantoniou, N; Pazos, A; Plasencia, W; Poon, LC; Rehal, A; Rolnik, DL; Syngelaki, A; Vojtassakova, D; Wright, D, 2017) |
| "The estimated rate of preeclampsia would be 4." | 5.42 | A Cost-Benefit Analysis of Low-Dose Aspirin Prophylaxis for the Prevention of Preeclampsia in the United States. ( Hauspurg, AK; Rouse, DJ; Werner, EF, 2015) |
| "This systematic review and meta-analysis investigated whether the use of low-dose aspirin during pregnancy by women with chronic hypertension reduces the odds of superimposed preeclampsia and poor perinatal outcomes." | 5.41 | Low-dose aspirin for the prevention of superimposed preeclampsia in women with chronic hypertension: a systematic review and meta-analysis. ( Giorgione, V; Richards, EMF; Stevens, O; Thilaganathan, B, 2023) |
| " The secondary outcomes included gestational hypertension; fetal growth restriction; preterm birth, either spontaneous or iatrogenic, before 34 weeks of gestation; gestational age at birth; neonatal birthweight; and adverse events secondary to the administration of aspirin, including antepartum and postpartum hemorrhage." | 5.41 | Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis. ( Acuti Martellucci, C; Buca, D; Cerra, C; D'Antonio, F; Fichera, A; Flacco, ME; Herrera, M; Khalil, A; Morelli, R; Orabona, R; Prefumo, F; Rizzo, G, 2023) |
| "Compared with aspirin alone, low-dose aspirin combined with calcium supplementation was more effective in preventing preeclampsia, reduced the risk of preterm birth and postpartum hemorrhage, and promoted fetal growth." | 5.41 | Clinical efficacy of low-dose aspirin combined with calcium in preventing preeclampsia: A systematic review and meta-analysis. ( Chen, WY; Sun, SF, 2023) |
| "To examine the possible risk factors amongst maternal characteristics, medical and obstetric history, pre-eclampsia (PE)-specific biomarkers and estimated-risk group, according to The Fetal Medicine Foundation (FMF) algorithm, that are associated with the development of preterm PE with delivery at < 37 weeks' gestation despite aspirin prophylaxis." | 5.41 | ASPRE trial: risk factors for development of preterm pre-eclampsia despite aspirin prophylaxis. ( Martinez-Portilla, RJ; Poon, LC; Rolnik, DL; Shen, L, 2021) |
| "Aspirin treatment enhanced LPS-stimulated TNFalpha production by PBML from controls but not cases." | 5.35 | Effect of aspirin treatment on TNFalpha production by women with a history of preterm birth. ( Cooper, C; Esplin, MS; Faux, DS; Hamblin, SD; Peltier, MR; Silver, RM, 2009) |
| " Meta-analyses of low-dose aspirin to prevent pre-eclampsia suggest that the incidence of preterm birth might also be decreased, particularly if initiated before 16 weeks of gestation." | 5.34 | Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. ( Achieng, E; Bose, CL; Carlo, WA; Chicuy, J; Chomba, E; Das, P; Derman, RJ; Esamai, F; Figueroa, L; Garces, A; Goco, N; Goldenberg, RL; Goudar, SS; Hemingway-Foday, J; Hibberd, PL; Hoffman, MK; Jessani, S; Kodkany, BS; Koso-Thomas, M; Krebs, NF; Kurhe, K; Liechty, EA; Lokangaka, A; McClure, EM; Metgud, M; Miodovnik, M; Moore, J; Mwapule, A; Mwenechanya, M; Nolen, TL; Nyongesa, P; Okitawutshu, J; Patel, A; Saleem, S; Silver, R; Somannavar, M; Tshefu, A; Zehra, F, 2020) |
| " The subjects of the study were randomly assigned into two groups of intervention and control to receive either 80 mg of aspirin or placebo daily during the pregnancy." | 5.34 | The effect of aspirin on preeclampsia, intrauterine growth restriction and preterm delivery among healthy pregnancies with a history of preeclampsia. ( Abdi, N; Alavi, A; Asadi, N; Hessami, K; Kasraeian, M; Rozrokh, A; Vafaei, H; Zare, S, 2020) |
| "Our objective was to determine whether low-dose aspirin reduces the rate of spontaneous preterm birth in nulliparous women without medical comorbidities." | 5.27 | Low-dose aspirin is associated with reduced spontaneous preterm birth in nulliparous women. ( Andrikopoulou, M; Gyamfi-Bannerman, C; Handal-Orefice, R; Purisch, SE, 2018) |
| " Trial will be individually randomized with one-to-one ratio (intervention/control) Population: Nulliparous women between the ages of 14 and 40, with a singleton pregnancy between 6 0/7 weeks and 13 6/7 weeks gestational age (GA) confirmed by ultrasound prior to enrollment, no more than two previous first trimester pregnancy losses, and no contraindications to aspirin." | 5.24 | A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study. ( Bose, CL; Carlo, WA; Chomba, E; Derman, RJ; Esamai, F; Garces, A; Goco, N; Goldenberg, RL; Goudar, SS; Hambidge, KM; Hemingway-Foday, JJ; Hibberd, PL; Hoffman, MK; Kodkany, BS; Koso-Thomas, M; Krebs, NF; Liechty, EA; Lokangaka, A; McClure, EM; Miodovnik, M; Mwenechanya, M; Patel, A; Saleem, S; Silver, R; Tshefu, A; Wallace, DD, 2017) |
| "To examine whether combined treatment with low-molecular-weight heparin (LMWH) and aspirin reduces recurrent hypertensive disorders of pregnancy (HD: pre-eclampsia, eclampsia or HELLP syndrome) in women with antiphospholipid antibodies (aPLA) and a previous delivery for HD and/or small-for-gestational-age (SGA) birthweight before 34 weeks gestation." | 5.22 | Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. ( Bezemer, D; de Vries, JI; Hague, WM; van Hoorn, ME; van Pampus, MG, 2016) |
| "The objective of this study is to determine whether low-dose aspirin (LDA) reduced the rate of preterm birth (PTB) in a cohort of women at high risk for preeclampsia." | 5.22 | The impact of low-dose aspirin on preterm birth: secondary analysis of a randomized controlled trial. ( Allshouse, AA; Heyborne, KD; Jessel, RH, 2016) |
| "Aspirin supplementation was associated with worse outcomes related to preterm birth in smokers in a high-risk but not low-risk cohort." | 5.20 | Low-dose aspirin, smoking status, and the risk of spontaneous preterm birth. ( Abramovici, A; Biggio, J; Cantu, J; Edwards, R; Jauk, V; Tita, A; Wetta, L, 2015) |
| "To evaluate the association between low-dose aspirin initiated before conception and the risk of preterm birth." | 5.20 | Low-dose aspirin and preterm birth: a randomized controlled trial. ( Ahrens, K; Faraggi, D; Galai, N; Lesher, LL; Lynch, AM; Mumford, SL; Perkins, NJ; Schisterman, EF; Silver, RM; Sjaarda, L; Townsend, JM; Wactawski-Wende, J; Wong, LF, 2015) |
| "To estimate the effect of early administration of aspirin on the prevention of pre-eclampsia in high-risk women." | 5.20 | Early prediction and aspirin for prevention of pre-eclampsia (EPAPP) study: a randomized controlled trial. ( Goetzinger, KR; Odibo, AO; Odibo, L; Tuuli, MG, 2015) |
| "To evaluate the effect of low-dose aspirin in prevention of adverse pregnancy outcomes (APO) in women with second trimester alpha-fetoprotein (AFP) >2." | 5.19 | Effect of aspirin in prevention of adverse pregnancy outcome in women with elevated alpha-fetoprotein. ( Alavi, A; Borna, S; Hantoushzadeh, S; Khazardoost, S; Khezerlou, N; Mousavi, S, 2014) |
| "Diagnosis of preeclampsia; adverse pregnancy health outcomes and complications including eclampsia, perinatal mortality, preterm birth, small for gestational age, and potential bleeding harms or infant/child harms from aspirin exposure." | 5.12 | Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. ( Henderson, JT; Redmond, N; Senger, CA; Thomas, RG; Vesco, KK, 2021) |
| " Aspirin prophylaxis substantially lowered the risk of pre-eclampsia, preterm birth, perinatal mortality, and intrauterine growth retardation without elevated bleeding risks." | 5.12 | Aspirin Prophylaxis During Pregnancy: A Systematic Review and Meta-Analysis. ( Choi, YJ; Shin, S, 2021) |
| "The results did not demonstrate a significant difference amongst low risk nulliparous women in the risks of pre-eclampsia or gestational hypertensive disorders with aspirin administration." | 5.12 | Aspirin for preventing adverse outcomes in low risk nulliparous women with singleton pregnancies: A systematic review and meta-analysis. ( Devani, P; Hodgetts Morton, V; Man, R; Morris, RK, 2021) |
| "To evaluate the use of low-molecular-weight heparin (LMWH) in combination with low-dose aspirin (LDA) for the treatment of antiphospholipid antibody (APA)-associated recurrent pregnancy loss and to compare the results with the use of unfractionated heparin (UFH) plus LDA." | 5.11 | Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. ( Franklin, RD; Herrada, J; Kutteh, WH; Lashey, N; Noble, LS, 2005) |
| "To perform a meta-analysis and meta-regression of randomized controlled trials (RCTs) to evaluate the impact of low-dose aspirin (LDA) on perinatal outcome, independent of its effect on pre-eclampsia (PE), preterm birth and low birth weight." | 5.05 | Impact of low-dose aspirin on adverse perinatal outcome: meta-analysis and meta-regression. ( Hartel, G; Kumar, S; Robertson, NT; Turner, JM, 2020) |
| "Administering low-dose aspirin to pregnant women led to small-to-moderate benefits, including reductions in pre-eclampsia (16 fewer per 1000 women treated), preterm birth (16 fewer per 1000 treated), the baby being born small-for-gestational age (seven fewer per 1000 treated) and fetal or neonatal death (five fewer per 1000 treated)." | 5.01 | Antiplatelet agents for preventing pre-eclampsia and its complications. ( Askie, LM; Duley, L; Hunter, KE; Meher, S; Seidler, AL, 2019) |
| "In high-risk pregnancies, early aspirin intervention starting before 16 weeks of gestation can prevent PIH, preeclampsia, IUGR, and preterm birth and help to increase the birth weight." | 4.91 | [Early intervention with aspirin for preventing preeclampsia in high-risk women: a meta-analysis]. ( Wu, H; Yao, S; Yu, Y, 2015) |
| "Databases were searched for keywords related to aspirin and pregnancy." | 4.89 | Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. ( Bujold, E; Demers, S; Nicolaides, KH; Roberge, S; Villa, P, 2013) |
| "To estimate the effect of low-dose aspirin started in early pregnancy on the incidence of preeclampsia and intrauterine growth restriction (IUGR)." | 4.86 | Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. ( Audibert, F; Bujold, E; Bureau, M; Forest, JC; Giguère, Y; Lacasse, Y; Marcoux, S; Roberge, S, 2010) |
| "This study aimed to investigate the association between low-dose aspirin use and preterm birth among women with a previous preterm birth." | 4.31 | Low-dose aspirin use in pregnancy and the risk of preterm birth: a Swedish register-based cohort study. ( Bergman, L; Hastie, R; Hesselman, S; Kupka, E; Lomartire, R; Wikström, AK, 2023) |
| "This study aimed to evaluate whether there is an association between the US Preventive Services Taskforce aspirin guideline hypertensive disorders of pregnancy and the rates of hypertensive disorders of pregnancy and preterm birth in individuals with pregestational diabetes mellitus." | 4.31 | Hypertensive disorders of pregnancy pre- and postaspirin guideline publication in individuals with pregestational diabetes mellitus. ( Allshouse, AA; Bruno, AM; Metz, TD; Theilen, LH, 2023) |
| " Among SLE group, lower birth weight and smaller gestational age were observed in SLE mothers with disease active during pregnancy, kidney involved, blood system involved and not taking Aspirin during pregnancy." | 4.31 | Association of preterm outcome with maternal systemic lupus erythematosus: a retrospective cohort study. ( Bei, F; Bu, J; Chen, X; Di, W; Hu, Y; Jiang, M; Sun, J; Wu, J; Ye, L, 2023) |
| "Prophylactic low-dose aspirin reduces the rates of preeclampsia, preterm birth, fetal growth restriction, and perinatal death in patients with risk factors for preeclampsia." | 4.31 | Society for Maternal-Fetal Medicine Special Statement: Prophylactic low-dose aspirin for preeclampsia prevention-quality metric and opportunities for quality improvement. ( Combs, CA; Kumar, NR; Morgan, JL, 2023) |
| "The USPSTF concludes with moderate certainty that there is a substantial net benefit of daily low-dose aspirin use to reduce the risk for preeclampsia, preterm birth, small for gestational age/intrauterine growth restriction, and perinatal mortality in pregnant persons at high risk for preeclampsia." | 4.02 | Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement. ( Barry, MJ; Cabana, M; Caughey, AB; Davidson, KW; Davis, EM; Donahue, KE; Doubeni, CA; Kubik, M; Li, L; Mangione, CM; Ogedegbe, G; Pbert, L; Silverstein, M; Simon, MA; Stevermer, J; Tseng, CW; Wong, JB, 2021) |
| " Among 932 women, 277 in the First Affiliated Hospital of Chongqing Medical University were routinely treated with aspirin (100 mg daily) from 12 to 16 weeks to 35 weeks of gestational age, while 655 in Chongqing Health Center for Women and Children were not taking aspirin during pregnancy." | 4.02 | Low-dose aspirin for primary prevention of adverse pregnancy outcomes in twin pregnancies: an observational cohort study based on propensity score matching. ( Baker, P; Kilby, MD; Liu, X; Liu, Y; Qi, H; Saffery, R; Tong, C; Wang, L; Wen, L; Ye, Y, 2021) |
| "Women with lupus have an increased risk of preeclampsia and preterm birth, and aspirin 81 mg/day is recommended as a preventative measure for preeclampsia." | 3.91 | Effect of aspirin response signature gene expression on preterm birth and preeclampsia among women with lupus: a pilot study. ( Clowse, MEB; Eudy, AM; Myers, RA; Voora, D, 2019) |
| "The use of low-dose aspirin in pregnancy should remain a highly targeted indication since its long-term safety has not been established and should be restricted to women at high risk of vascular complications." | 3.85 | [For a targeted use of aspirin]. ( Brun, S; Coatleven, F; Gleyze, M; Lecoq, C; Madar, H; Merlot, B; Nithart, A; Sentilhes, L, 2017) |
| "The beneficial effect of aspirin in the prevention of preterm preeclampsia may not apply in pregnancies with chronic hypertension." | 3.85 | Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. ( Akolekar, R; De Stefani, L; Delgado, JL; Evangelinakis, N; Gonzalez-Vanegas, O; Jani, JC; Leipold, G; Nicolaides, KH; Persico, N; Plasencia, W; Poon, LC; Rolnik, DL; Shearing, S; Syngelaki, A; Tsokaki, T; Wright, D, 2017) |
| " Risk factors for pregnancy complications, including premature delivery before 34 gestational weeks, hypertensive disorders of pregnancy, thrombocytopenia, and light-for-date neonate, were evaluated in 51 women who received low dose aspirin (LDA) plus unfractionated heparin (UFH) and delivered after 24 GW." | 3.85 | Factors associated with adverse pregnancy outcomes in women with antiphospholipid syndrome: A multicenter study. ( Deguchi, M; Fujita, D; Makino, S; Miki, A; Morikawa, M; Murashima, A; Sugiura-Ogasawara, M; Yamada, H, 2017) |
| "This prospective study aimed to evaluate pregnancy outcome and complications in women with recurrent pregnancy loss (RPL) and protein S (PS) deficiency, who received low dose aspirin (LDA) or LDA plus heparin (LDA/H) therapies." | 3.83 | Protein S deficiency complicated pregnancy in women with recurrent pregnancy loss. ( Deguchi, M; Ebina, Y; Morizane, M; Shinozaki, N; Tanimura, K; Yamada, H, 2016) |
| "To identify patients at very high risk for adverse pregnancy outcome (APO) at the 20- to 23-week scan and to assess the effectiveness of Aspirin (ASS) and low molecular weight heparin (LMWH) starting after this examination." | 3.79 | Individual risk assessment of adverse pregnancy outcome by multivariate regression analysis may serve as basis for drug intervention studies: retrospective analysis of 426 high-risk patients including ethical aspects. ( Becker, R; Bittner, U; Fangerau, H; Keller, T; Kiesewetter, H, 2013) |
| "The aim of this study was to evaluate whether low doses of aspirin (100 mg per day) administered to a homogeneous population of women early (8-10 weeks) during their first pregnancy improved the outcome of gestation hypertensive disorders." | 3.77 | Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation. ( Bakhti, A; Vaiman, D, 2011) |
| "The incidence of preterm preeclampsia was 1." | 3.30 | Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial. ( Alsius, M; Bonacina, E; Caamiña, S; Carreras, E; de Mingo, L; Diaz, S; Ferrer-Costa, R; Garcia, E; Garcia-Manau, P; López, M; Lopez-Quesada, E; Maiz, N; Maroto, A; Martin, L; Mendoza, M; Millán, P; Ocaña, V; Orizales-Lago, C; Pallarols, M; Pérez-Gomez, A; Pintado, E; Puerto, L; Ricart, M; Rodríguez-Zurita, A; Suy, A; Teixidor, M; Vidal-Sagnier, L; Vives, À, 2023) |
| "ASA use during pregnancy has benefits beyond reducing the risk of pre-eclampsia." | 3.01 | The Role of Acetylsalicylic Acid in the Prevention of Pre-Eclampsia, Fetal Growth Restriction, and Preterm Birth. ( Berger, R; Hinz, B; Stubert, J, 2023) |
| "The risk of preeclampsia was not different when comparing the aspirin and placebo groups among the Hispanic, non-Hispanic black, or other ethnicity and race groups." | 2.94 | Low-dose aspirin for preeclampsia prevention: efficacy by ethnicity and race. ( Aagaard, KM; Mendez-Figueroa, H; Sangi-Haghpeykar, H; Tolcher, MC, 2020) |
| "The Aspirin for Evidence-Based Preeclampsia Prevention trial data are consistent with the hypothesis that aspirin delays the gestational age at delivery with preeclampsia." | 2.90 | Aspirin delays the development of preeclampsia. ( Nicolaides, KH; Wright, D, 2019) |
| "When aspirin was initiated at > 16 weeks, with a dosage of < 100 mg/day aspirin, there was a lesser preventive effect (RR = 0." | 2.82 | The role of aspirin dose and initiation time in the prevention of preeclampsia and corresponding complications: a meta-analysis of RCTs. ( Dai, C; He, Q; Huang, X; Lee, W; Li, L; Li, R; Luo, Z; Mok, TN; Yip, KC; Zeng, W, 2022) |
| "Placental insufficiency affects about 10% of pregnancies and can lead to pre-eclampsia, fetal growth restriction, and preterm birth." | 2.82 | The role of melatonin in pregnancies complicated by placental insufficiency: A systematic review. ( Bussolaro, S; Fantasia, I; Rolnik, DL; Stampalija, T, 2022) |
| "When superimposed preeclampsia was present, it developed at an earlier gestational age among the group without GDM (35 ± 5 vs." | 2.82 | Rate of Gestational Diabetes Mellitus and Pregnancy Outcomes in Patients with Chronic Hypertension. ( Blackwell, SC; Haidar, ZA; Leon, MG; Longo, M; Mendez-Figueroa, H; Moussa, HN; Pedroza, C; Sibai, BM, 2016) |
| "Preterm birth is the leading cause of neonatal morbidity and mortality worldwide." | 2.66 | Current Preterm Birth Prevention Strategies. ( Breslin, N; Gyamfi-Bannerman, C, 2020) |
| " Avoidance of nephrotoxic and teratogenic medications is necessary, and renal dosing of commonly used medications must also be considered." | 2.61 | Chronic Kidney Disease and Pregnancy. ( Hladunewich, MA; Hui, D, 2019) |
| "Women at an increased risk of preeclampsia should be offered antiplatelet therapy, regardless of whether they are first seen before or after 16 weeks' gestation." | 2.55 | Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis. ( Askie, L; Duley, L; Hunter, K; Meher, S, 2017) |
| "Spontaneous preterm birth is an important cause of neonatal mortality and morbidity." | 2.55 | Antiplatelet Agents and the Prevention of Spontaneous Preterm Birth: A Systematic Review and Meta-analysis. ( Askie, LA; Mol, BWJ; Oudijk, MA; van Vliet, EOG, 2017) |
| " Careful attention must be paid to the dosing and potential teratogenicity of medications." | 2.52 | Pregnancy and Lupus Nephritis. ( Garovic, VD; Kattah, AG, 2015) |
| "Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality." | 2.50 | Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. ( Henderson, JT; O'Connor, E; Rowland, MG; Senger, CA; Thompson, JH; Whitlock, EP, 2014) |
| "Preeclampsia, intrauterine growth restriction (IUGR), and placental abruption are obstetrical conditions that constitute the syndrome of ischemic placental disease or IPD, the leading cause of indicated preterm birth and an important cause of neonatal morbidity and mortality." | 2.50 | Prediction and prevention of ischemic placental disease. ( Cleary, KL; Friedman, AM, 2014) |
| "Antiphospholipid syndrome is one of the few treatable causes of pregnancy loss, and successful pregnancy rates of 70% or more can be achieved with appropriate treatment." | 2.44 | [Pregnancy and antiphospholipid antibodies]. ( Goffinet, F; Le Guern, V, 2008) |
| "Premature birth is associated with an increased risk of mortality and morbidity, and strategies to prevent preterm birth are few in number and resource intensive." | 1.91 | Cost-effectiveness of low-dose aspirin for the prevention of preterm birth: a prospective study of the Global Network for Women's and Children's Health Research. ( Achieng, E; Bose, CL; Bresnahan, BW; Bucher, S; Carlo, WA; Chicuy, J; Chomba, E; Das, P; Derman, RJ; Esamai, F; Figueroa, L; Goco, N; Goldenberg, RL; Goudar, SS; Hibberd, PL; Hoffman, M; Jessani, S; Kavi, A; Koso-Thomas, M; Krebs, NF; Kurhe, K; Liechty, EA; Lokangaka, A; McClure, EM; Metgud, M; Moore, J; Mwapule, A; Mwenechanya, M; Neuwahl, S; Nyongesa, P; Okitawutshu, J; Patel, A; Patterson, JK; Saleem, S; Somannavar, M; Tshefu, A, 2023) |
| " In age-adjusted analyses, aspirin plus LMWH regardless of dosage was associated with significantly higher odds of live birth compared with no antithrombotic use (OR = 7." | 1.91 | Management and outcomes of women with antiphospholipid syndrome during pregnancy. ( Adurty, S; D'Angelo, D; DeSancho, MT; Tao, JJ, 2023) |
| "· High-risk patients who lack a history preeclampsia were less likely to be advised of aspirin use." | 1.62 | Improving Utilization of Aspirin for Prevention of Preeclampsia in a High-Risk Urban Cohort: A Prospective Cohort Study. ( Berghella, V; Boelig, RC; Roman, A; Wanees, M; Zhan, T, 2021) |
| "The Aspirin for Evidence-Based Preeclampsia Prevention trial was a multicenter study in women with singleton pregnancies." | 1.46 | Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. ( Carbone, IF; de Alvarado, M; Delgado, JL; Dutemeyer, V; Kapeti, E; Nicolaides, KH; Papantoniou, N; Pazos, A; Plasencia, W; Poon, LC; Rehal, A; Rolnik, DL; Syngelaki, A; Vojtassakova, D; Wright, D, 2017) |
| "The rate of preeclampsia was much higher at quintile (Q) 5 of VAT depth (9." | 1.46 | Preeclampsia and Preterm Birth Associated With Visceral Adiposity in Early Pregnancy. ( Berger, H; Bujold, E; Connelly, PW; De Souza, LR; Park, AL; Ray, JG, 2017) |
| "The estimated rate of preeclampsia would be 4." | 1.42 | A Cost-Benefit Analysis of Low-Dose Aspirin Prophylaxis for the Prevention of Preeclampsia in the United States. ( Hauspurg, AK; Rouse, DJ; Werner, EF, 2015) |
| "(2) Influence of treatment on the pregnancy outcomes and complications: 24 APS patients were given the treatment of aspirin or aspirin combined with low molecular weight heparin, and 30 patients received no treatment." | 1.40 | [Pregnancy outcome in 54 patients with antiphospholipid syndrome: a retrospective clinical study]. ( Deng, XL; Liu, XY; Zheng, XJ, 2014) |
| "Preterm birth was more frequent in study group than general population (21." | 1.38 | Obstetrical outcome of anti-inflammatory and anticoagulation therapy in women with recurrent pregnancy loss or unexplained infertility. ( Ahn, H; Beaman, K; Gilman-Sachs, A; Han, AR; Kwak-Kim, J; Park, JC; Vu, P, 2012) |
| "Preterm birth is associated with elevated production of pro-inflammatory cytokines such as TNFalpha at the maternal-fetal interface." | 1.36 | Cytokine production by peripheral blood mononuclear cells of women with a history of preterm birth. ( Esplin, MS; Faux, DS; Hamblin, SD; Peltier, MR; Silver, RM, 2010) |
| "Aspirin treatment enhanced LPS-stimulated TNFalpha production by PBML from controls but not cases." | 1.35 | Effect of aspirin treatment on TNFalpha production by women with a history of preterm birth. ( Cooper, C; Esplin, MS; Faux, DS; Hamblin, SD; Peltier, MR; Silver, RM, 2009) |
| "Antiphospholipid syndrome is a recognized disorder of pregnancy." | 1.33 | Maternal and fetal complications of antiphospholipid syndrome: a case report with long-term follow-up. ( Khurshid, M; Naru, T; Nazir, Z, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (3.60) | 29.6817 |
| 2010's | 50 (45.05) | 24.3611 |
| 2020's | 57 (51.35) | 2.80 |
| Authors | Studies |
|---|---|
| Davidson, KW | 1 |
| Barry, MJ | 1 |
| Mangione, CM | 1 |
| Cabana, M | 1 |
| Caughey, AB | 1 |
| Davis, EM | 1 |
| Donahue, KE | 1 |
| Doubeni, CA | 1 |
| Kubik, M | 1 |
| Li, L | 2 |
| Ogedegbe, G | 1 |
| Pbert, L | 1 |
| Silverstein, M | 1 |
| Simon, MA | 1 |
| Stevermer, J | 1 |
| Tseng, CW | 1 |
| Wong, JB | 1 |
| Henderson, JT | 2 |
| Vesco, KK | 1 |
| Senger, CA | 2 |
| Thomas, RG | 1 |
| Redmond, N | 1 |
| Ye, Y | 1 |
| Wen, L | 1 |
| Liu, X | 1 |
| Wang, L | 1 |
| Liu, Y | 2 |
| Saffery, R | 1 |
| Kilby, MD | 1 |
| Tong, C | 1 |
| Qi, H | 1 |
| Baker, P | 1 |
| Reis de Carvalho, C | 1 |
| Bigotte Vieira, M | 1 |
| Costa, J | 1 |
| Vaz Carneiro, A | 1 |
| Yip, KC | 1 |
| Luo, Z | 1 |
| Huang, X | 1 |
| Lee, W | 1 |
| Dai, C | 1 |
| Zeng, W | 1 |
| Mok, TN | 1 |
| He, Q | 1 |
| Li, R | 1 |
| Ray, JG | 2 |
| Abdulaziz, KE | 1 |
| Berger, H | 2 |
| Landman, AJEMC | 3 |
| de Boer, MA | 3 |
| Visser, L | 1 |
| Nijman, TAJ | 1 |
| Hemels, MAC | 1 |
| Naaktgeboren, CN | 1 |
| van der Weide, MC | 1 |
| Mol, BW | 2 |
| van Laar, JOEH | 1 |
| Papatsonis, DNM | 1 |
| Bekker, MN | 1 |
| van Drongelen, J | 1 |
| van Pampus, MG | 2 |
| Sueters, M | 1 |
| van der Ham, DP | 1 |
| Sikkema, JM | 1 |
| Zwart, JJ | 1 |
| Huisjes, AJM | 1 |
| van Huizen, ME | 1 |
| Kleiverda, G | 1 |
| Boon, J | 1 |
| Franssen, MTM | 1 |
| Hermes, W | 1 |
| Visser, H | 1 |
| de Groot, CJM | 1 |
| Oudijk, MA | 4 |
| Hodgetts Morton, V | 2 |
| Stock, SJ | 1 |
| Katler, QS | 1 |
| Kawwass, JF | 1 |
| Hurst, BS | 1 |
| Sparks, AE | 1 |
| McCulloh, DH | 1 |
| Wantman, E | 1 |
| Toner, JP | 1 |
| Bauserman, M | 2 |
| Leuba, SI | 1 |
| Hemingway-Foday, J | 3 |
| Nolen, TL | 2 |
| Moore, J | 4 |
| McClure, EM | 5 |
| Lokangaka, A | 5 |
| Tsehfu, A | 1 |
| Patterson, J | 1 |
| Liechty, EA | 5 |
| Esamai, F | 5 |
| Carlo, WA | 5 |
| Chomba, E | 5 |
| Goldenberg, RL | 5 |
| Saleem, S | 5 |
| Jessani, S | 4 |
| Koso-Thomas, M | 4 |
| Hoffman, M | 2 |
| Derman, RJ | 5 |
| Meshnick, SR | 1 |
| Bose, CL | 4 |
| Kasraeian, M | 2 |
| Asadi, N | 2 |
| Vafaei, H | 2 |
| Tazang, M | 1 |
| Rahimirad, N | 1 |
| Yousofi, S | 1 |
| Khaleghi, SF | 1 |
| Zare, M | 1 |
| van Limburg Stirum, EVJ | 1 |
| van 't Hooft, J | 1 |
| Leemhuis, AG | 1 |
| Finken, MJJ | 1 |
| van Baar, AL | 1 |
| Roseboom, TJ | 1 |
| Ravelli, ACJ | 1 |
| van Wely, M | 1 |
| Oosterlaan, J | 1 |
| Painter, RC | 1 |
| Pajkrt, E | 1 |
| Kupka, E | 2 |
| Hesselman, S | 2 |
| Hastie, R | 3 |
| Lomartire, R | 2 |
| Wikström, AK | 2 |
| Bergman, L | 2 |
| Fantasia, I | 1 |
| Bussolaro, S | 1 |
| Stampalija, T | 1 |
| Rolnik, DL | 6 |
| Richards, EMF | 1 |
| Giorgione, V | 1 |
| Stevens, O | 1 |
| Thilaganathan, B | 1 |
| Kawaguchi, H | 1 |
| Kanagawa, T | 1 |
| Yamamoto, R | 1 |
| Sasahara, J | 1 |
| Okamoto, Y | 1 |
| Mitsuda, N | 1 |
| Ishii, K | 1 |
| D'Antonio, F | 3 |
| Khalil, A | 3 |
| Rizzo, G | 3 |
| Fichera, A | 3 |
| Herrera, M | 3 |
| Buca, D | 3 |
| Morelli, R | 3 |
| Cerra, C | 3 |
| Orabona, R | 3 |
| Acuti Martellucci, C | 3 |
| Flacco, ME | 3 |
| Prefumo, F | 3 |
| Bruno, AM | 1 |
| Allshouse, AA | 2 |
| Metz, TD | 1 |
| Theilen, LH | 1 |
| Magee, LA | 1 |
| von Dadelszen, P | 1 |
| Patterson, JK | 1 |
| Neuwahl, S | 1 |
| Goco, N | 4 |
| Goudar, SS | 4 |
| Metgud, M | 3 |
| Somannavar, M | 3 |
| Kavi, A | 2 |
| Okitawutshu, J | 3 |
| Tshefu, A | 4 |
| Mwapule, A | 2 |
| Mwenechanya, M | 3 |
| Chicuy, J | 2 |
| Figueroa, L | 3 |
| Krebs, NF | 4 |
| Kurhe, K | 3 |
| Das, P | 3 |
| Patel, A | 3 |
| Hibberd, PL | 4 |
| Achieng, E | 3 |
| Nyongesa, P | 3 |
| Bucher, S | 2 |
| Bresnahan, BW | 1 |
| Dimitriadis, E | 1 |
| Zhou, W | 1 |
| Estrada-Gutierrez, G | 1 |
| Koga, K | 1 |
| Francisco, RPV | 1 |
| Whitehead, C | 1 |
| Hyett, J | 2 |
| da Silva Costa, F | 2 |
| Nicolaides, K | 1 |
| Menkhorst, E | 1 |
| Mendoza, M | 2 |
| Bonacina, E | 1 |
| Garcia-Manau, P | 1 |
| López, M | 1 |
| Caamiña, S | 1 |
| Vives, À | 1 |
| Lopez-Quesada, E | 1 |
| Ricart, M | 1 |
| Maroto, A | 1 |
| de Mingo, L | 1 |
| Pintado, E | 1 |
| Ferrer-Costa, R | 1 |
| Martin, L | 1 |
| Rodríguez-Zurita, A | 1 |
| Garcia, E | 1 |
| Pallarols, M | 1 |
| Vidal-Sagnier, L | 1 |
| Teixidor, M | 1 |
| Orizales-Lago, C | 1 |
| Pérez-Gomez, A | 1 |
| Ocaña, V | 1 |
| Puerto, L | 1 |
| Millán, P | 1 |
| Alsius, M | 1 |
| Diaz, S | 1 |
| Maiz, N | 1 |
| Carreras, E | 2 |
| Suy, A | 2 |
| Fischer-Betz, R | 1 |
| Joudi, N | 1 |
| Rode, M | 1 |
| Tao, JJ | 1 |
| Adurty, S | 1 |
| D'Angelo, D | 1 |
| DeSancho, MT | 1 |
| Chen, X | 1 |
| Di, W | 1 |
| Ye, L | 1 |
| Hu, Y | 1 |
| Jiang, M | 1 |
| Wu, J | 1 |
| Bu, J | 1 |
| Sun, J | 1 |
| Bei, F | 1 |
| Norooznezhad, AH | 1 |
| Nabavian, SM | 1 |
| Stephenson, DJ | 1 |
| MacKnight, HP | 1 |
| Hoeferlin, LA | 1 |
| Washington, SL | 1 |
| Sawyers, C | 1 |
| Archer, KJ | 1 |
| Strauss, JF | 1 |
| Walsh, SW | 1 |
| Chalfant, CE | 1 |
| Combs, CA | 1 |
| Kumar, NR | 1 |
| Morgan, JL | 1 |
| Parchem, JG | 1 |
| Sibai, BM | 3 |
| Stubert, J | 1 |
| Hinz, B | 1 |
| Berger, R | 1 |
| Hoffman, MK | 5 |
| Nuss, EE | 2 |
| Tembo, AM | 1 |
| Silver, RM | 5 |
| Chen, WY | 1 |
| Sun, SF | 1 |
| Xiao, ZQ | 1 |
| Li, DZ | 1 |
| Mirzamoradi, M | 1 |
| Dehghani, Z | 1 |
| Azadi, P | 1 |
| Mohammadi, M | 1 |
| Khavandegar, A | 1 |
| Bakhtiyari, M | 1 |
| Turner, JM | 1 |
| Robertson, NT | 1 |
| Hartel, G | 1 |
| Kumar, S | 1 |
| Duley, L | 2 |
| Meher, S | 2 |
| Hunter, KE | 1 |
| Seidler, AL | 1 |
| Askie, LM | 1 |
| Eudy, AM | 1 |
| Voora, D | 1 |
| Myers, RA | 1 |
| Clowse, MEB | 1 |
| Quinlivan, JA | 1 |
| Kodkany, BS | 2 |
| Garces, A | 2 |
| Zehra, F | 1 |
| Miodovnik, M | 2 |
| Silver, R | 2 |
| Rodriguez-Pintó, I | 1 |
| Espinosa, G | 1 |
| Cervera, R | 1 |
| Brentisci, A | 1 |
| Delorme, P | 1 |
| Abdi, N | 1 |
| Rozrokh, A | 1 |
| Alavi, A | 2 |
| Zare, S | 1 |
| Hessami, K | 1 |
| Yang, Z | 1 |
| Shen, X | 1 |
| Zhou, C | 1 |
| Wang, M | 1 |
| Zhou, L | 1 |
| Boelig, RC | 1 |
| Wanees, M | 1 |
| Zhan, T | 1 |
| Berghella, V | 1 |
| Roman, A | 1 |
| Breslin, N | 1 |
| Gyamfi-Bannerman, C | 2 |
| Tolcher, MC | 1 |
| Sangi-Haghpeykar, H | 1 |
| Mendez-Figueroa, H | 2 |
| Aagaard, KM | 1 |
| Huai, J | 1 |
| Lin, L | 1 |
| Juan, J | 1 |
| Chen, J | 1 |
| Li, B | 1 |
| Zhu, Y | 1 |
| Yu, M | 1 |
| Yang, H | 1 |
| Tong, S | 1 |
| Walker, S | 1 |
| Cluver, C | 1 |
| Choi, YJ | 1 |
| Shin, S | 1 |
| Shen, L | 1 |
| Martinez-Portilla, RJ | 1 |
| Poon, LC | 3 |
| Man, R | 1 |
| Devani, P | 1 |
| Morris, RK | 1 |
| Rode, L | 1 |
| Ekelund, CK | 1 |
| Riishede, I | 1 |
| Rasmussen, S | 1 |
| Lidegaard, Ø | 1 |
| Tabor, A | 1 |
| Madar, H | 1 |
| Brun, S | 1 |
| Coatleven, F | 1 |
| Nithart, A | 1 |
| Lecoq, C | 1 |
| Gleyze, M | 1 |
| Merlot, B | 1 |
| Sentilhes, L | 1 |
| Käehne, LV | 1 |
| Rørbye, C | 1 |
| Wallace, DD | 1 |
| Hemingway-Foday, JJ | 1 |
| Hambidge, KM | 1 |
| Iriye, BK | 1 |
| Gregory, KD | 1 |
| Saade, GR | 1 |
| Grobman, WA | 1 |
| Brown, HL | 1 |
| Wright, D | 3 |
| Syngelaki, A | 2 |
| Delgado, JL | 2 |
| Tsokaki, T | 1 |
| Leipold, G | 1 |
| Akolekar, R | 1 |
| Shearing, S | 1 |
| De Stefani, L | 1 |
| Jani, JC | 1 |
| Plasencia, W | 2 |
| Evangelinakis, N | 1 |
| Gonzalez-Vanegas, O | 1 |
| Persico, N | 1 |
| Nicolaides, KH | 4 |
| Deguchi, M | 2 |
| Yamada, H | 2 |
| Sugiura-Ogasawara, M | 1 |
| Morikawa, M | 1 |
| Fujita, D | 1 |
| Miki, A | 1 |
| Makino, S | 1 |
| Murashima, A | 1 |
| O'Gorman, N | 1 |
| Roberge, S | 4 |
| Bujold, E | 5 |
| Uzan, S | 1 |
| Beaufils, M | 1 |
| Vojtassakova, D | 1 |
| de Alvarado, M | 1 |
| Kapeti, E | 1 |
| Rehal, A | 1 |
| Pazos, A | 1 |
| Carbone, IF | 1 |
| Dutemeyer, V | 1 |
| Papantoniou, N | 1 |
| Connell, MT | 1 |
| Sjaarda, LA | 1 |
| Radin, RG | 1 |
| Kuhr, D | 1 |
| Mumford, SL | 2 |
| Plowden, TC | 1 |
| Schisterman, EF | 2 |
| El-Messidi, A | 1 |
| Andrikopoulou, M | 1 |
| Purisch, SE | 1 |
| Handal-Orefice, R | 1 |
| Li, YY | 1 |
| Gu, QR | 1 |
| Chen, GR | 1 |
| Quinn, MJ | 1 |
| Govindaswami, B | 1 |
| Jegatheesan, P | 1 |
| Nudelman, M | 1 |
| Narasimhan, SR | 1 |
| Mikolaiczik, K | 1 |
| Praetner, M | 1 |
| Rüth, M | 1 |
| Mark, K | 1 |
| Egan, AM | 1 |
| Brassill, MJ | 1 |
| Brosnan, E | 1 |
| Carmody, L | 1 |
| Clarke, H | 1 |
| Coogan Kelly, C | 1 |
| Culliney, L | 1 |
| Durkan, M | 1 |
| Fenlon, M | 1 |
| Ferry, P | 1 |
| Hanlon, G | 1 |
| Higgins, T | 1 |
| Hoashi, S | 1 |
| Khamis, A | 1 |
| Kinsley, B | 1 |
| Kinsley, T | 1 |
| Kirwan, B | 1 |
| Liew, A | 1 |
| McGurk, C | 1 |
| McHugh, C | 1 |
| Murphy, MS | 1 |
| Murphy, P | 1 |
| O'Halloran, D | 1 |
| O'Mahony, L | 1 |
| O'Sullivan, E | 1 |
| Nolan, M | 1 |
| Peter, M | 1 |
| Roberts, G | 1 |
| Smyth, A | 1 |
| Todd, M | 1 |
| Tuthill, A | 1 |
| Wan Mahmood, WA | 1 |
| Yousif, O | 1 |
| P Dunne, F | 1 |
| Ayala, NK | 1 |
| Rouse, DJ | 2 |
| Hui, D | 1 |
| Hladunewich, MA | 1 |
| Dewarrat, N | 1 |
| Kaiser, J | 1 |
| Baud, D | 1 |
| Alberio, L | 1 |
| Gavillet, M | 1 |
| Groeneveld, E | 1 |
| Lambers, MJ | 1 |
| Lambalk, CB | 1 |
| Broeze, KA | 1 |
| Haapsamo, M | 1 |
| de Sutter, P | 1 |
| Schoot, BC | 1 |
| Schats, R | 1 |
| Hompes, PG | 1 |
| Khazardoost, S | 1 |
| Mousavi, S | 1 |
| Borna, S | 1 |
| Hantoushzadeh, S | 1 |
| Khezerlou, N | 1 |
| Whitlock, EP | 1 |
| O'Connor, E | 1 |
| Thompson, JH | 1 |
| Rowland, MG | 1 |
| Zheng, XJ | 1 |
| Deng, XL | 1 |
| Liu, XY | 1 |
| Friedman, AM | 1 |
| Cleary, KL | 1 |
| Voelker, R | 1 |
| Abramovici, A | 1 |
| Jauk, V | 1 |
| Wetta, L | 1 |
| Cantu, J | 1 |
| Edwards, R | 1 |
| Biggio, J | 1 |
| Tita, A | 1 |
| Moussa, HN | 2 |
| Wu, ZH | 1 |
| Han, Y | 1 |
| Pacheco, LD | 1 |
| Blackwell, SC | 2 |
| Saade, G | 1 |
| Costantine, MM | 1 |
| Ahrens, K | 1 |
| Wong, LF | 1 |
| Perkins, NJ | 1 |
| Galai, N | 1 |
| Lesher, LL | 1 |
| Faraggi, D | 1 |
| Wactawski-Wende, J | 1 |
| Townsend, JM | 1 |
| Lynch, AM | 1 |
| Sjaarda, L | 1 |
| Odibo, AO | 1 |
| Goetzinger, KR | 1 |
| Odibo, L | 1 |
| Tuuli, MG | 1 |
| Yao, S | 1 |
| Wu, H | 1 |
| Yu, Y | 1 |
| Werner, EF | 1 |
| Hauspurg, AK | 1 |
| Kattah, AG | 1 |
| Garovic, VD | 1 |
| van Hoorn, ME | 1 |
| Hague, WM | 1 |
| Bezemer, D | 1 |
| de Vries, JI | 2 |
| Leon, MG | 1 |
| Longo, M | 1 |
| Pedroza, C | 1 |
| Haidar, ZA | 1 |
| Jessel, RH | 1 |
| Heyborne, KD | 1 |
| Shinozaki, N | 1 |
| Ebina, Y | 1 |
| Tanimura, K | 1 |
| Morizane, M | 1 |
| Abheiden, CN | 1 |
| Blomjous, BS | 1 |
| Kroese, SJ | 1 |
| Bultink, IE | 1 |
| Fritsch-Stork, RD | 1 |
| Lely, AT | 1 |
| Gernand, AD | 1 |
| Simhan, HN | 1 |
| Baca, KM | 1 |
| Caritis, S | 1 |
| Bodnar, LM | 1 |
| Hunter, K | 1 |
| Askie, L | 1 |
| De Souza, LR | 1 |
| Park, AL | 1 |
| Connelly, PW | 1 |
| van Vliet, EOG | 1 |
| Askie, LA | 1 |
| Mol, BWJ | 1 |
| Le Guern, V | 1 |
| Goffinet, F | 1 |
| Peltier, MR | 2 |
| Faux, DS | 2 |
| Hamblin, SD | 2 |
| Cooper, C | 1 |
| Esplin, MS | 2 |
| Lacasse, Y | 1 |
| Bureau, M | 1 |
| Audibert, F | 1 |
| Marcoux, S | 1 |
| Forest, JC | 1 |
| Giguère, Y | 2 |
| Tapp, S | 1 |
| Bakhti, A | 1 |
| Vaiman, D | 1 |
| Han, AR | 1 |
| Ahn, H | 1 |
| Vu, P | 1 |
| Park, JC | 1 |
| Gilman-Sachs, A | 1 |
| Beaman, K | 1 |
| Kwak-Kim, J | 1 |
| Demers, S | 1 |
| Villa, P | 1 |
| Becker, R | 1 |
| Keller, T | 1 |
| Kiesewetter, H | 1 |
| Fangerau, H | 1 |
| Bittner, U | 1 |
| Noble, LS | 1 |
| Kutteh, WH | 1 |
| Lashey, N | 1 |
| Franklin, RD | 1 |
| Herrada, J | 1 |
| Naru, T | 1 |
| Khurshid, M | 1 |
| Nazir, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Best Practice Alert (BPA) for Low Dose Aspirin Recommendation in High-risk Pregnancies: a Randomized Controlled Trial[NCT05802940] | 640 participants (Anticipated) | Interventional | 2023-06-19 | Not yet recruiting | |||
| Implementing Screening for Preeclampsia in Norway With Aspirin Discontinuation at 24-28 Weeks - a Randomized Controlled Trial[NCT06108947] | 300 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | |||
| 162 mg of Aspirin for Prevention of Preeclampsia[NCT05221164] | Phase 4 | 200 participants (Anticipated) | Interventional | 2021-07-06 | Recruiting | ||
| Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity[NCT05757167] | Phase 4 | 2,500 participants (Anticipated) | Interventional | 2023-11-06 | Recruiting | ||
| Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
| Genetic, Laboratory and Clinical Factors Associated With Low-dose Aspirin Failure in the Prevention of Preeclampsia- An Exploratory Protocol[NCT05709483] | Early Phase 1 | 130 participants (Anticipated) | Interventional | 2023-04-13 | Recruiting | ||
| Prevention of Maternal and Neonatal Death/Infections With a Single Oral Dose of Azithromycin in Women in Labor (in Low- and Middle-income Countries): a Randomized Controlled Trial[NCT03871491] | Phase 3 | 34,000 participants (Anticipated) | Interventional | 2020-09-01 | Active, not recruiting | ||
| STUDY PROTOCOL FOR A PROSPECTIVE, MULTICENTRE, COHORT STUDY: Preeclampsia Sequential Screening Using Angiogenic Factors During First Trimester of Pregnancy (CRISP STUDY)[NCT04767438] | 6,560 participants (Anticipated) | Observational | 2021-03-31 | Not yet recruiting | |||
| First-trimester Preeclampsia Screening: Women's Perspectives[NCT05123560] | 750 participants (Anticipated) | Observational | 2022-04-01 | Not yet recruiting | |||
| A Randomized Controlled Trial Comparing Low Doses Of Aspirin In The Prevention Of Preeclampsia (ASAPP)[NCT04070573] | Phase 3 | 400 participants (Anticipated) | Interventional | 2019-10-21 | Enrolling by invitation | ||
| Aspirin Versus Metformin in Pregnancies at High Risk of Preterm Preeclampsia: a 3-arm Randomized Controlled Trial[NCT05580523] | 3,000 participants (Anticipated) | Interventional | 2023-07-03 | Recruiting | |||
| A Prospective Muti-center Study of Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort[NCT04631627] | Phase 4 | 1,500 participants (Anticipated) | Interventional | 2020-11-16 | Not yet recruiting | ||
| Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia[NCT04797949] | Phase 4 | 156 participants (Anticipated) | Interventional | 2021-03-03 | Recruiting | ||
| Prevention of Preeclampsia With Aspirin Administered From the Beginning of Pregnancy in Recipients of Donated Oocytes.[NCT02174328] | Phase 3 | 81 participants (Actual) | Interventional | 2014-05-21 | Terminated (stopped due to Halted prematurely due to low recruitment rate.) | ||
| Low Dose Aspirin in the Prevention of Preeclampsia in Chinese Pregnant Women.[NCT02797249] | Phase 3 | 1,000 participants (Actual) | Interventional | 2016-12-07 | Completed | ||
| Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension: A Pilot Study[NCT04908982] | Phase 4 | 60 participants (Anticipated) | Interventional | 2021-05-28 | Recruiting | ||
| Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy (PIPSICKLE): a Randomized Controlled Trial[NCT05253781] | Phase 3 | 476 participants (Anticipated) | Interventional | 2020-07-01 | Recruiting | ||
| The Effects of Aspirin in Gestation and Reproduction: A Multi-center, Controlled, Double-blind Randomized Trial.[NCT00467363] | 1,228 participants (Actual) | Interventional | 2007-06-30 | Completed | |||
| Early Prediction and Aspirin for Prevention of Preeclampsia[NCT01547390] | 104 participants (Actual) | Interventional | 2012-03-31 | Terminated (stopped due to Terminated after Aspirin was recommended by the USPTF to Prevent Preeclampsia.) | |||
| Prospective Validation of Prediction Algorithms for Preeclampsia in the First-trimester of Pregnancy[NCT03554681] | 10,935 participants (Actual) | Observational | 2016-12-31 | Completed | |||
| Low-molecular-weight Heparin Versus Unfractionated Heparin in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome. A Randomized Controlled Trial[NCT01051778] | Phase 2 | 60 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 189 |
| Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1078 |
| Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 78 |
| Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 303 |
| Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 134 |
| Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 141 |
| Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 42 |
| Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 352 |
| Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 264 |
| Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 668 |
| Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1506 |
| Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 214 |
| Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 26 |
| Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 54 |
| Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 9 |
| Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 23 |
| Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 290 |
| Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 8 |
| Placebo Arm | 21 |
Partial or complete abruption (ie, premature separation of the placenta) (NCT00467363)
Timeframe: until delivery
| Intervention | participants (Number) |
|---|---|
| Aspirin | 7 |
| Placebo | 5 |
(NCT00467363)
Timeframe: 8-weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 374 |
| Placebo | 346 |
Implantation failures (NCT00467363)
Timeframe: 8 weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 28 |
| Placebo | 27 |
(NCT00467363)
Timeframe: within 6 weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 3 |
| Placebo | 3 |
(NCT00467363)
Timeframe: until 40 weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 4 |
| Placebo | 6 |
(NCT00467363)
Timeframe: within 8-weeks of gestation
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 394 |
| Placebo | 363 |
Live birth was obtained prospectively by maternal report and abstraction from medical records by trained staff . (NCT00467363)
Timeframe: after delivery
| Intervention | livebirths (Number) |
|---|---|
| Aspirin | 309 |
| Placebo | 286 |
(NCT00467363)
Timeframe: 8 weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 0 |
| Placebo | 0 |
(NCT00467363)
Timeframe: until delivery
| Intervention | participants (Number) |
|---|---|
| Aspirin | 32 |
| Placebo | 30 |
Includes preembryonic and embryonic losses (exclusive of implantation failures) (NCT00467363)
Timeframe: less than 10-weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 56 |
| Placebo | 53 |
(NCT00467363)
Timeframe: until delivery
| Intervention | infants (Number) |
|---|---|
| Aspirin | 22 |
| Placebo | 31 |
birthweight (NCT00467363)
Timeframe: until delivery
| Intervention | grams (Mean) |
|---|---|
| Aspirin | 3327 |
| Placebo | 3315 |
(NCT00467363)
Timeframe: 40 weeks
| Intervention | participants (Number) |
|---|---|
| Aspirin | 2 |
| Placebo | 2 |
Preeclampsia diagnosed per ACOG criteria: Blood pressure greater than 140/90 on 2 occasions 6 hrs apart and significant proteinuria (greater than 300mg in 24hrs). (NCT01547390)
Timeframe: within 3 months prior to delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 3 |
| Aspirin | 3 |
"Intrauterine growth restriction (IUGR) - estimated fetal weight less than 10th percentile early preeclampsia - preeclampsia delivered prior to 34 weeks severe preeclampsia - blood pressure greater then 160/110 gestational hypertension - hypertension without features of preeclampsia preterm birth, stillbirth, placental abruption, antepartum hemorrhage, neonatal death, NICU admission, miscarriage.~Statistical significance not reported due to the low recruitment and poor patient compliance." (NCT01547390)
Timeframe: within 3 months of delivery
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Small for gestational age (IUGR) | Gestational hypertension | Early preeclampsia | Severe preeclampsia | Preterm birth | Stillbirth | Placental abruption | antepartum hemorrhage | neonatal death | NICU admission | miscarriage | |
| Aspirin | 1 | 2 | 1 | 3 | 1 | 0 | 0 | 0 | 0 | 2 | 0 |
| Placebo | 1 | 0 | 1 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 1 |
Live birth occurs when a fetus (> 24 weeks ) , exits the maternal body and subsequently shows signs of life, such as voluntary movement, heartbeat, or pulsation of the umbilical cord. (NCT01051778)
Timeframe: pregnancy > 24weeks gestation
| Intervention | Percentage of pregnancies (Number) |
|---|---|
| Enoxaparin 40 mg /Day Plus Low Dose Aspirin | 24 |
| Heparin Calcium 5,000 U Twice Daily Plus Low Dose Aspirin | 20 |
34 reviews available for aspirin and Preterm Birth
| Article | Year |
|---|---|
Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Infant, Newborn; Infant, Small for | 2021 |
The role of aspirin dose and initiation time in the prevention of preeclampsia and corresponding complications: a meta-analysis of RCTs.
Topics: Aspirin; Female; Humans; Infant, Newborn; Platelet Aggregation Inhibitors; Postpartum Hemorrhage; Pr | 2022 |
Low-dose aspirin for the prevention of preterm birth: More questions than answers.
Topics: Abortion, Habitual; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Infant, Newbor | 2022 |
Vanquishing multiple pregnancy in in vitro fertilization in the United States-a 25-year endeavor.
Topics: Acetaminophen; Aspirin; Female; Fertilization in Vitro; Humans; Infant, Low Birth Weight; Infant, Ne | 2022 |
The role of melatonin in pregnancies complicated by placental insufficiency: A systematic review.
Topics: Antioxidants; Aspirin; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Melatonin; Placent | 2022 |
Low-dose aspirin for the prevention of superimposed preeclampsia in women with chronic hypertension: a systematic review and meta-analysis.
Topics: Aspirin; Female; Humans; Hypertension; Infant, Newborn; Perinatal Death; Pre-Eclampsia; Pregnancy; P | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Aspirin for prevention of preeclampsia and adverse perinatal outcome in twin pregnancies: a systematic review and meta-analysis.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Hypertension, Pregnancy-Induced; In | 2023 |
Pre-eclampsia.
Topics: Aspirin; Female; Humans; Hypertension; Infant, Newborn; Perinatal Death; Pre-Eclampsia; Pregnancy; P | 2023 |
Aspirin in pregnancy: a review of indications, timing, dosing and efficacy.
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Infant, Small for Gestational Ag | 2023 |
The Role of Acetylsalicylic Acid in the Prevention of Pre-Eclampsia, Fetal Growth Restriction, and Preterm Birth.
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Pre-Eclampsia; Pregnancy; Premat | 2023 |
The great obstetrical syndromes and the placenta.
Topics: Aspirin; Female; Humans; Infant, Newborn; Inflammation; Placenta; Pre-Eclampsia; Pregnancy; Prematur | 2023 |
Clinical efficacy of low-dose aspirin combined with calcium in preventing preeclampsia: A systematic review and meta-analysis.
Topics: Aspirin; Calcium; Calcium, Dietary; Female; Humans; Hypertension, Pregnancy-Induced; Infant, Newborn | 2023 |
Impact of low-dose aspirin on adverse perinatal outcome: meta-analysis and meta-regression.
Topics: Abruptio Placentae; Apgar Score; Aspirin; Delivery, Obstetric; Female; Fetal Growth Retardation; Hum | 2020 |
Antiplatelet agents for preventing pre-eclampsia and its complications.
Topics: Aspirin; Female; Gestational Age; Humans; Infant, Newborn; Infant, Small for Gestational Age; Matern | 2019 |
Prevention of recurrent miscarriage in women with antiphospholipid syndrome: A systematic review and network meta-analysis.
Topics: Abortion, Habitual; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Heparin, | 2021 |
Current Preterm Birth Prevention Strategies.
Topics: Administration, Intravaginal; Aspirin; Cerclage, Cervical; Cervical Length Measurement; Female; Fert | 2020 |
Aspirin to prevent pre-eclampsia.
Topics: Aspirin; Drug Administration Schedule; Female; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2021 |
Aspirin Prophylaxis During Pregnancy: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Female; Gestational Age; Humans; Infant, Newborn; Pre-Eclampsia; Pregnancy; Pregnancy Outco | 2021 |
Aspirin for preventing adverse outcomes in low risk nulliparous women with singleton pregnancies: A systematic review and meta-analysis.
Topics: Aspirin; Female; Humans; Infant, Newborn; Infant, Small for Gestational Age; Pre-Eclampsia; Pregnanc | 2021 |
[Treatment with low-dose acetylsalicylic acid can reduce risk of pre-eclampsia in high-risk pregnant women].
Topics: Aspirin; Early Medical Intervention; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Peri | 2017 |
The Effects of Aspirin in Gestation and Reproduction (EAGeR) Trial: A Story of Discovery.
Topics: Adolescent; Adult; Aspirin; C-Reactive Protein; Female; Humans; Pregnancy; Pregnancy Complications; | 2017 |
Prevention of Prematurity: Advances and Opportunities.
Topics: Anti-Infective Agents; Aspirin; Cerclage, Cervical; Cesarean Section; Female; Humans; Indomethacin; | 2018 |
Chronic Kidney Disease and Pregnancy.
Topics: Aspirin; Female; Glomerular Filtration Rate; Humans; Hypertension, Pregnancy-Induced; Infant, Newbor | 2019 |
Preconceptional low-dose aspirin for the prevention of hypertensive pregnancy complications and preterm delivery after IVF: a meta-analysis with individual patient data.
Topics: Adult; Aspirin; Female; Fertilization in Vitro; Humans; Hypertension, Pregnancy-Induced; Logistic Mo | 2013 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pr | 2014 |
Prediction and prevention of ischemic placental disease.
Topics: Abruptio Placentae; Anticoagulants; Ascorbic Acid; Aspirin; Calcium, Dietary; Dietary Supplements; F | 2014 |
[Early intervention with aspirin for preventing preeclampsia in high-risk women: a meta-analysis].
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Humans; Infant, Newborn; Pre-Eclampsia; Pre | 2015 |
Committee Opinion Summary No. 638: First-Trimester Risk Assessment for Early-Onset Preeclampsia.
Topics: Advisory Committees; Age of Onset; Aspirin; Early Diagnosis; Evidence-Based Medicine; Female; Follow | 2015 |
Pregnancy and Lupus Nephritis.
Topics: Abortion, Spontaneous; Anticoagulants; Antihypertensive Agents; Antiphospholipid Syndrome; Aspirin; | 2015 |
Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis.
Topics: Aspirin; Female; Humans; Infant, Newborn; Infant, Small for Gestational Age; Perinatal Death; Platel | 2017 |
Antiplatelet Agents and the Prevention of Spontaneous Preterm Birth: A Systematic Review and Meta-analysis.
Topics: Adult; Aspirin; Dipyridamole; Female; Gestational Age; Humans; Logistic Models; Platelet Aggregation | 2017 |
[Pregnancy and antiphospholipid antibodies].
Topics: Animals; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Complemen | 2008 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Incidence; Platelet Aggregation | 2010 |
Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis.
Topics: Aspirin; Female; Fetal Death; Fetal Growth Retardation; Humans; Perinatal Mortality; Platelet Aggreg | 2013 |
24 trials available for aspirin and Preterm Birth
| Article | Year |
|---|---|
Evaluation of low-dose aspirin in the prevention of recurrent spontaneous preterm labour (the APRIL study): A multicentre, randomised, double-blinded, placebo-controlled trial.
Topics: Adult; Aspirin; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Netherlands; | 2022 |
The efficacy of low-dose aspirin in pregnancy among women in malaria-endemic countries.
Topics: Aspirin; Female; Humans; Infant, Newborn; Malaria; Perinatal Death; Perinatal Mortality; Pregnancy; | 2022 |
The effect of 150 and 80 mg doses of aspirin on preventing preterm birth in high-risk pregnant women.
Topics: Aspirin; Female; Humans; Infant, Newborn; Iran; Placenta; Pre-Eclampsia; Pregnancy; Pregnant Women; | 2022 |
Long-term outcomes following antenatal exposure to low-dose aspirin: study protocol for the 4-year follow-up of the APRIL randomised controlled trial.
Topics: Aspirin; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Infant, Newborn; Pregnancy; Pre | 2022 |
Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial.
Topics: Adult; Aspirin; Biomarkers; Female; Hemorrhage; Humans; Infant, Newborn; Peripartum Period; Placenta | 2023 |
The impact of risk factors on aspirin's efficacy for the prevention of preterm birth.
Topics: Aspirin; Female; Humans; Hypertension, Pregnancy-Induced; Infant, Newborn; Male; Perinatal Death; Pr | 2023 |
Evaluation of the Effect of Low-dose Aspirin on the Prevention of Preterm Delivery in Women with a History of Spontaneous Preterm Delivery.
Topics: Aspirin; Female; Gestational Age; Humans; Incidence; Infant, Newborn; Pre-Eclampsia; Pregnancy; Prem | 2023 |
Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aspirin; Blood Pressure; Delivery, Obstetric; Developing Countries; Double-Blind | 2020 |
Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aspirin; Blood Pressure; Delivery, Obstetric; Developing Countries; Double-Blind | 2020 |
Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aspirin; Blood Pressure; Delivery, Obstetric; Developing Countries; Double-Blind | 2020 |
Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aspirin; Blood Pressure; Delivery, Obstetric; Developing Countries; Double-Blind | 2020 |
The effect of aspirin on preeclampsia, intrauterine growth restriction and preterm delivery among healthy pregnancies with a history of preeclampsia.
Topics: Adult; Aspirin; Female; Fetal Growth Retardation; Humans; Pre-Eclampsia; Pregnancy; Pregnancy-Associ | 2020 |
Low-dose aspirin for preeclampsia prevention: efficacy by ethnicity and race.
Topics: Aspirin; Ethnicity; Female; Humans; Infant, Newborn; Placenta; Pre-Eclampsia; Pregnancy; Premature B | 2020 |
Preventive effect of aspirin on preeclampsia in high-risk pregnant women with stage 1 hypertension.
Topics: Aspirin; China; Female; Humans; Hypertension; Infant, Newborn; Pre-Eclampsia; Pregnancy; Pregnant Wo | 2021 |
ASPRE trial: risk factors for development of preterm pre-eclampsia despite aspirin prophylaxis.
Topics: Adult; Algorithms; Arterial Pressure; Aspirin; Biomarkers; Blood Pressure; Female; Gestational Age; | 2021 |
A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Developing Countries; Double-Bl | 2017 |
A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Developing Countries; Double-Bl | 2017 |
A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Developing Countries; Double-Bl | 2017 |
A description of the methods of the aspirin supplementation for pregnancy indicated risk reduction in nulliparas (ASPIRIN) study.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Developing Countries; Double-Bl | 2017 |
Low-dose aspirin is associated with reduced spontaneous preterm birth in nulliparous women.
Topics: Administration, Oral; Adolescent; Aspirin; Female; Gestational Age; Humans; Parity; Platelet Aggrega | 2018 |
Aspirin delays the development of preeclampsia.
Topics: Adult; Aspirin; Female; Gestational Age; Humans; Platelet Aggregation Inhibitors; Pre-Eclampsia; Pre | 2019 |
Effect of aspirin in prevention of adverse pregnancy outcome in women with elevated alpha-fetoprotein.
Topics: Adult; alpha-Fetoproteins; Aspirin; Female; Fetal Death; Humans; Pre-Eclampsia; Pregnancy; Pregnancy | 2014 |
Low-dose aspirin, smoking status, and the risk of spontaneous preterm birth.
Topics: Adolescent; Adult; Aspirin; Cohort Studies; Double-Blind Method; Female; Humans; Infant, Newborn; In | 2015 |
Customized versus Population Fetal Growth Norms and Adverse Outcomes Associated with Small for Gestational Age Infants in a High-Risk Cohort.
Topics: Aspirin; Birth Weight; Cesarean Section; Cyclooxygenase Inhibitors; Female; Fetal Development; Fetal | 2015 |
Low-dose aspirin and preterm birth: a randomized controlled trial.
Topics: Adult; Aspirin; Cyclooxygenase Inhibitors; Female; Folic Acid; Humans; Intention to Treat Analysis; | 2015 |
Early prediction and aspirin for prevention of pre-eclampsia (EPAPP) study: a randomized controlled trial.
Topics: Adult; Aspirin; Double-Blind Method; Female; Gestational Age; Humans; Platelet Aggregation Inhibitor | 2015 |
Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT.
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Australia; Drug Therapy, Co | 2016 |
Rate of Gestational Diabetes Mellitus and Pregnancy Outcomes in Patients with Chronic Hypertension.
Topics: Adult; Aspirin; Diabetes, Gestational; Female; Gestational Age; Humans; Hypertension; Infant, Newbor | 2016 |
The impact of low-dose aspirin on preterm birth: secondary analysis of a randomized controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Female; F | 2016 |
Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin.
Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Anticoagulants; Aspirin; Drug Therapy, Comb | 2005 |
53 other studies available for aspirin and Preterm Birth
| Article | Year |
|---|---|
Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Infant, Newborn; Infant, Small for | 2021 |
Low-dose aspirin for primary prevention of adverse pregnancy outcomes in twin pregnancies: an observational cohort study based on propensity score matching.
Topics: Adult; Aspirin; China; Cohort Studies; Female; Humans; Infant, Small for Gestational Age; Pre-Eclamp | 2021 |
[Analysis of the Cochrane Review: Antiplatelet Agents for Preventing Pre-Eclampsia and Its Complications. Cochrane Database Syst Rev. 2019;10:CD004659.]
Topics: Aspirin; Female; Humans; Infant, Newborn; Platelet Aggregation Inhibitors; Pre-Eclampsia; Pregnancy; | 2021 |
Aspirin Use for Preeclampsia Prevention Among Women With Prepregnancy Diabetes, Obesity, and Hypertension.
Topics: Adolescent; Adult; Aspirin; Female; Humans; Hypertension; Length of Stay; Obesity; Pre-Eclampsia; Pr | 2022 |
Low-dose aspirin use in pregnancy and the risk of preterm birth: a Swedish register-based cohort study.
Topics: Aspirin; Cohort Studies; Female; Humans; Infant, Newborn; Platelet Aggregation Inhibitors; Pregnancy | 2023 |
Efficacy of discontinuing the use of low-dose aspirin at 28 weeks of gestation for preventing preeclampsia.
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Hypertension; Infant, Newborn; Postpartum Hemorrh | 2022 |
Hypertensive disorders of pregnancy pre- and postaspirin guideline publication in individuals with pregestational diabetes mellitus.
Topics: Aspirin; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension, Pregnancy-Induced | 2023 |
Aspirin from early pregnancy to reduce preterm birth.
Topics: Aspirin; Female; Humans; Infant, Newborn; Pre-Eclampsia; Pregnancy; Pregnancy Outcome; Premature Bir | 2023 |
Cost-effectiveness of low-dose aspirin for the prevention of preterm birth: a prospective study of the Global Network for Women's and Children's Health Research.
Topics: Aspirin; Child; Child Health; Cost-Benefit Analysis; Female; Humans; Infant, Newborn; Perinatal Deat | 2023 |
[Update on pregnancy in inflammatory rheumatic diseases].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Female; Humans; Infant, New | 2023 |
Management and outcomes of women with antiphospholipid syndrome during pregnancy.
Topics: Antiphospholipid Syndrome; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Infant, Newborn; | 2023 |
Association of preterm outcome with maternal systemic lupus erythematosus: a retrospective cohort study.
Topics: Aspirin; Birth Weight; Child; China; Female; Humans; Infant; Infant, Newborn; Infant, Premature; Lup | 2023 |
Low-dose aspirin and prevention of preterm birth: untold story of inflammation.
Topics: Aspirin; Female; Humans; Infant, Newborn; Inflammation; Platelet Aggregation Inhibitors; Pre-Eclamps | 2023 |
Preterm birth and the mechanism of action of low-dose aspirin: a response.
Topics: Aspirin; Female; Humans; Infant, Newborn; Pre-Eclampsia; Premature Birth | 2023 |
Bioactive lipid mediators in plasma are predictors of preeclampsia irrespective of aspirin therapy.
Topics: Aspirin; Biomarkers; Cross-Sectional Studies; Eicosanoids; Female; Humans; Infant, Newborn; Placenta | 2023 |
Society for Maternal-Fetal Medicine Special Statement: Prophylactic low-dose aspirin for preeclampsia prevention-quality metric and opportunities for quality improvement.
Topics: Aspirin; Female; Humans; Infant, Newborn; Perinatology; Pre-Eclampsia; Pregnancy; Premature Birth; Q | 2023 |
Aspirin Discontinuation in Pregnancies at High Risk of Preterm Preeclampsia-Reply.
Topics: Aspirin; Female; Humans; Infant, Newborn; Pre-Eclampsia; Pregnancy; Pregnancy, High-Risk; Premature | 2023 |
Aspirin Discontinuation in Pregnancies at High Risk of Preterm Preeclampsia.
Topics: Aspirin; Female; Humans; Infant, Newborn; Pre-Eclampsia; Pregnancy; Pregnancy, High-Risk; Premature | 2023 |
Reply to: Is it possible for prevention of preterm birth with aspirin?
Topics: Aspirin; Female; Humans; Infant, Newborn; Pre-Eclampsia; Premature Birth | 2023 |
Is it possible for prevention of preterm birth with aspirin?
Topics: Aspirin; Female; Humans; Infant, Newborn; Pre-Eclampsia; Premature Birth | 2023 |
Effect of aspirin response signature gene expression on preterm birth and preeclampsia among women with lupus: a pilot study.
Topics: Adult; Aspirin; Female; Gene Expression; Humans; Intracellular Signaling Peptides and Proteins; Lupu | 2019 |
Simple and safe: preventing preterm birth with aspirin.
Topics: Aspirin; Double-Blind Method; Female; Humans; Infant, Newborn; Parity; Pregnancy; Premature Birth | 2020 |
Precision medicine and the antiphospholipid syndrome: what is the future?
Topics: Abortion, Spontaneous; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; An | 2020 |
[Can low dose aspirin be proposed to reduce preterm birth, if started in the early pregnancy?]
Topics: Aspirin; Female; Humans; Infant, Newborn; Pre-Eclampsia; Pregnancy; Premature Birth | 2020 |
Improving Utilization of Aspirin for Prevention of Preeclampsia in a High-Risk Urban Cohort: A Prospective Cohort Study.
Topics: Adult; Aspirin; Cohort Studies; Drug Administration Schedule; Female; Gestational Age; Humans; Plate | 2021 |
Prediction of preterm pre-eclampsia according to NICE and ACOG criteria: descriptive study of 597 492 Danish births from 2008 to 2017.
Topics: Adult; Aspirin; Denmark; Female; Gestational Age; Humans; Incidence; Infant, Newborn; Obstetrics; Pr | 2021 |
[For a targeted use of aspirin].
Topics: Abnormalities, Drug-Induced; Antiphospholipid Syndrome; Aspirin; Female; Humans; Pre-Eclampsia; Preg | 2017 |
Quality measures in high-risk pregnancies: Executive Summary of a Cooperative Workshop of the Society for Maternal-Fetal Medicine, National Institute of Child Health and Human Development, and the American College of Obstetricians and Gynecologists.
Topics: Antibiotic Prophylaxis; Aspirin; Cesarean Section; Congresses as Topic; Female; Fetal Growth Retarda | 2017 |
Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history.
Topics: Adult; Algorithms; Aspirin; Body Mass Index; Evidence-Based Medicine; Female; Gestational Age; Human | 2017 |
Factors associated with adverse pregnancy outcomes in women with antiphospholipid syndrome: A multicenter study.
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; Heparin; Humans; Hy | 2017 |
Early screening and prevention of preterm pre-eclampsia with aspirin: time for clinical implementation.
Topics: Aspirin; Early Diagnosis; Female; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as To | 2017 |
Early screening and prevention of preterm pre-eclampsia with aspirin: time for clinical implementation.
Topics: Aspirin; Early Diagnosis; Female; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as To | 2017 |
Early screening and prevention of preterm pre-eclampsia with aspirin: time for clinical implementation.
Topics: Aspirin; Early Diagnosis; Female; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as To | 2017 |
Early screening and prevention of preterm pre-eclampsia with aspirin: time for clinical implementation.
Topics: Aspirin; Early Diagnosis; Female; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as To | 2017 |
Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia.
Topics: Adult; Aspirin; Double-Blind Method; Ethnicity; Evidence-Based Medicine; Female; Humans; Logistic Mo | 2017 |
Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia.
Topics: Adult; Aspirin; Double-Blind Method; Ethnicity; Evidence-Based Medicine; Female; Humans; Logistic Mo | 2017 |
Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia.
Topics: Adult; Aspirin; Double-Blind Method; Ethnicity; Evidence-Based Medicine; Female; Humans; Logistic Mo | 2017 |
Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia.
Topics: Adult; Aspirin; Double-Blind Method; Ethnicity; Evidence-Based Medicine; Female; Humans; Logistic Mo | 2017 |
Excerpts from the World Medical Literature: Obstetrics.
Topics: Aspirin; Female; Humans; Infant, Newborn; Obstetrics; Pre-Eclampsia; Pregnancy; Premature Birth; Vit | 2018 |
Preventing preterm preeclampsia.
Topics: Aspirin; Female; Humans; Infant, Newborn; Obstetric Labor, Premature; Pre-Eclampsia; Pregnancy; Prem | 2018 |
Delayed hemolysis, elevated liver enzymes, low platelet count syndrome in succession of switches of preventive anticoagulant treatment in a 41-year-old patient with a history of recurrent assisted implantation failures: a case report.
Topics: Adult; Anticoagulants; Aspirin; Cesarean Section; Female; HELLP Syndrome; Heparin, Low-Molecular-Wei | 2019 |
An Irish National Diabetes in Pregnancy Audit: aiming for best outcomes for women with diabetes.
Topics: Abortion, Spontaneous; Adult; Aspirin; Cesarean Section; Clinical Audit; Delivery of Health Care; De | 2020 |
A Nudge Toward Universal Aspirin for Preeclampsia Prevention.
Topics: Aspirin; Attitude of Health Personnel; Female; Guideline Adherence; Humans; Platelet Aggregation Inh | 2019 |
Low-dose aspirin as a promising agent for the prevention of spontaneous preterm birth.
Topics: Aspirin; Female; Humans; Infant, Newborn; Parity; Pregnancy; Premature Birth | 2019 |
Pregnancy with Chuvash Polycythaemia and Other Congenital Erythrocytosis.
Topics: Adult; Aspirin; Female; Ferritins; Heparin, Low-Molecular-Weight; Homozygote; Humans; Iron; Polycyth | 2020 |
[Pregnancy outcome in 54 patients with antiphospholipid syndrome: a retrospective clinical study].
Topics: Abortion, Spontaneous; Antiphospholipid Syndrome; Aspirin; Female; Fetal Growth Retardation; Heparin | 2014 |
USPSTF: Low-dose aspirin may help reduce risk of preeclampsia.
Topics: Advisory Committees; Aspirin; Female; Fetal Growth Retardation; Humans; Platelet Aggregation Inhibit | 2014 |
A Cost-Benefit Analysis of Low-Dose Aspirin Prophylaxis for the Prevention of Preeclampsia in the United States.
Topics: Administration, Oral; Aspirin; Cost-Benefit Analysis; Decision Support Techniques; Dose-Response Rel | 2015 |
Protein S deficiency complicated pregnancy in women with recurrent pregnancy loss.
Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Aspirin; Birth Weight; Comorbidity; Drug Th | 2016 |
Low-molecular-weight heparin and aspirin use in relation to pregnancy outcome in women with systemic lupus erythematosus and antiphospholipid syndrome: A cohort study.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Databases, Factual; Female; Heparin, Low- | 2017 |
Vitamin D, pre-eclampsia, and preterm birth among pregnancies at high risk for pre-eclampsia: an analysis of data from a low-dose aspirin trial.
Topics: Adult; Aspirin; Female; Fibrinolytic Agents; Humans; Pre-Eclampsia; Pregnancy; Pregnancy Complicatio | 2017 |
Preeclampsia and Preterm Birth Associated With Visceral Adiposity in Early Pregnancy.
Topics: Adult; Aspirin; Body Mass Index; Chronic Disease; Female; Humans; Hypertension; Intra-Abdominal Fat; | 2017 |
Effect of aspirin treatment on TNFalpha production by women with a history of preterm birth.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Cells; Case-Control Studies; Cells, C | 2009 |
Cytokine production by peripheral blood mononuclear cells of women with a history of preterm birth.
Topics: Aspirin; Cytokines; Escherichia coli; Female; Humans; Interleukin-10; Interleukin-1beta; Interleukin | 2010 |
Opinion & hypothesis could early aspirin prophylaxis prevent against preterm birth?
Topics: Aspirin; Female; Fibrinolytic Agents; Humans; Meta-Analysis as Topic; Pregnancy; Premature Birth | 2011 |
Prevention of gravidic endothelial hypertension by aspirin treatment administered from the 8th week of gestation.
Topics: Adult; Aspirin; Birth Weight; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Fetal | 2011 |
Obstetrical outcome of anti-inflammatory and anticoagulation therapy in women with recurrent pregnancy loss or unexplained infertility.
Topics: Abortion, Habitual; Anti-Inflammatory Agents; Anticoagulants; Aspirin; Diabetes, Gestational; Female | 2012 |
Individual risk assessment of adverse pregnancy outcome by multivariate regression analysis may serve as basis for drug intervention studies: retrospective analysis of 426 high-risk patients including ethical aspects.
Topics: Algorithms; Anticoagulants; Aspirin; Body Mass Index; Female; Fetal Death; Fetal Growth Retardation; | 2013 |
Maternal and fetal complications of antiphospholipid syndrome: a case report with long-term follow-up.
Topics: Abortion, Habitual; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Follow-Up Stu | 2006 |